Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.59
Peer-review started: October 30, 2023
First decision: November 8, 2023
Revised: December 6, 2023
Accepted: December 18, 2023
Article in press: December 18, 2023
Published online: January 27, 2024
Processing time: 86 Days and 22.2 Hours
Severe acute pancreatitis (SAP) accounts for 20% of all acute pancreatitis cases and poses a more serious threat to human health, so it is necessary to provide timely intervention to patients to improve their outcomes and ensure a certain therapeutic effect.
In view of the limited studies on the efficacy and safety of somatostatin (SS) combined with computerized tomography-guided therapeutic percutaneous puncture catheter drainage (CT-TPPCD) in the treatment of SAP, this study aims to supplement the gaps in this area and provide reliable clinical guidance.
To analyze the efficacy and safety of CT-TPPCD combined with SS in the treatment of SAP.
Forty-two SAP patients were included, including 20 cases (control group) treated with SS intervention and 22 cases (research group) with CT-TPPCD + SS intervention. Comparative analyses were conducted from the following perspectives: Efficacy, safety (pancreatic fistula, intraperitoneal hemorrhage, sepsis, and organ dysfunction syndrome), abdominal bloating and pain relief time, intestinal recovery time, length of hospital stay, inflammatory indicators (C-reactive protein, interleukin-6, and procalcitonin), and Acute Physiology and Chronic Health Evaluation (APACHE) II score.
The research group showed a higher total effective rate than the control group, with faster relief of abdominal bloating and pain and intestinal recovery, shorter length of hospital stay, and fewer adverse events, all with statistical significance. In addition, lower levels of inflammation indexes and APACHE II scores were determined in the research group after treatment, significantly lower than the baseline and those of the control group.
CT-TPPCD plus SS is highly effective and safe in the treatment of SAP patients, contributing to fast inhibition of patients' disease and effective alleviation of serum inflammatory responses, which is worthy of clinical promotion.
The negative impact of SAP on patients should not be underestimated, and it is necessary to improve clinical efficacy from the perspective of treatment optimization. This study proposes that SS combined with CT-TPPCD is significantly superior to SS alone in the treatment of SAP, which is of great significance for improving the clinical outcome of SAP patients and provides new clinical basis and insights.